CDMOs/CMOs: The Key Moves in 2026
What have been key moves—capacity additions and acquisitions by CDMOs of drug substances (small molecules and biologics) thus far in 2026? A roundup of key developments.
AmbioPharm
CordenPharma Acquires AmbioPharm to Expand Peptide API Capacity
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Ambiopharm Breaks Ground on $28 Million Expansion
Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.
AmbioPharm Appoints Brian Gregg as CEO
Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.
Ariceum and AmbioPharm in Peptide Partnership
Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers, and AmbioPharm, a globally oriented US CDMO specialized in peptides, have agreed a strategic partnership in peptide conjugates.
Streamlining the Path to Peptide Market Supply
Interview with Michael Postlethwaite, Senior Director, Sales & Business Development, European Territories, AmbioPharm
